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Malic enzyme 2 (ME2) catalyzes the formation of pyruvate from malic acid and is
abnormally expressed in some tumors. However, the exact effects of ME2 on
proneural–mesenchymal transition (PMT) and lipogenesis in glioblastoma multiforme
(GBM) remain unexplored. Here, we found that ME2 expression was significantly higher
in GBM than in normal brain tissues and negatively correlated with overall survival of
patients with GBM. Furthermore, we demonstrated that ME2 was positively correlated
with mesenchymal features in GBM and promoted proliferation, migration, and invasion of
glioma cells. Moreover, ME2 upregulated the expression of mesenchymal markers
(N-cadherin, vimentin, YKL40, and MET), whereas it inhibited the expression of
proneural maker OLIG2, indicating that ME2 might promote PMT in GBM. We also
found that ME2 inhibited the production of mitochondrial reactive oxygen species and
AMPK phosphorylation, resulting in SREBP-1 maturation and nuclear localization and
enhancing the ACSS2 lipogenesis pathway. Taken together, these results suggest that
ME2 promotes PMT and is linked with reprogramming of lipogenesis via AMPK–SREBP-
1–ACSS2 signaling in GBM. Therefore, ME2 has potential as a new classification marker in
GBM and could provide a new approach to glioma treatment.
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Glioblastoma multiforme (GBM) is the most common and fatal malignant primary brain tumor in
adults, with a 5-year survival rate of less than 5% (1). Central nervous system tumors are classified as
grade I to IV by the World Health Organization (WHO) according to histological and molecular
characteristics, and the most advanced (grade IV) astrocytomas are classified as GBM (2–4).
Moreover, the different GBM phenotypes, which include proneural (PN), neural, classical, and
mesenchymal (MES) phenotypes, are relevant to the clinical treatment of recurrent brain tumors
(5–7). The MES phenotype is the most malignant and is associated with the worst prognosis, and the
PN phenotype tends to transform into the MES phenotype (8, 9). This PN–MES transition (PMT), a
process similar to the epithelial–mesenchymal transition (EMT) that occurs in a variety of cancers,
is a key event driving invasion, tumorigenesis, and development of gliomas (10–12). In PMT, MES
markers (including MET, vimentin, N-cadherin, and YKL-40) are positively correlated with tumorJuly 2021 | Volume 11 | Article 7155931
Yang et al. ME2 Promotes PMT in GBMgrade growth, metastasis, and progression, whereas PN markers
(E-cadherin, OLIG2) are not (13). Despite these findings, the
precise mechanism of PMT remains undetermined.
Multiple metabolic pathways create a complex network that
promotes the cross-communication between oncogenic and
tumor metabolic pathways and promotes tumor progression
(14). AMP-activated protein kinase (AMPK) acts as an energy
sensor in regulating cellular energy and plays a key role in the
upregulation of catabolism and inactivation of anabolism (15).
Accumulating evidence has highlighted that lipid metabolism
reprogramming is a hallmark of cancer, contributing to cancer
transformation and glioma progression (16–19). Sterol-
regulatory element binding protein 1 (SREBP-1), an
intracellular cholesterol sensor located in the endoplasmic
reticulum, positively regulates lipogenesis (20, 21). Cytoplasmic
acetyl-CoA is the central precursor of lipid biosynthesis,
produced by ATP-citrate lyase (ACLY) from mitochondria or
acetyl-CoA synthetase short-chain family member 2 (ACSS2).
The ACSS2 reaction can compensate for the loss of ACLY (22,
23). Previous studies have confirmed that malic enzyme 2 (ME2),
a key enzyme in the tricarboxylic acid (TCA) cycle, is abnormally
expressed in some malignant tumors, including melanoma (24),
non–small-cell lung cancer (25), and pancreatic cancer (26).
Moreover, ME2 is involved in a series of processes, including
tumor growth, metastasis, and malignant transformation (27–
29). In addition, ME2 has a profound effect on lipogenesis and
glutamine metabolism; however, its role in the PMT process in
GBM has not previously been investigated (28).
In this study, we demonstrated that the mechanism of ME2
promoted PMT and lipogenesis. We found that ME2 is
associated with overall survival of patients and promotes the
proliferation, migration, and invasion of glioma cells.
Importantly, to our knowledge, ME2 promoted PMT of glioma
cells and reprogrammed lipogenesis via the AMPK–SREBP-1–
ACSS2 pathway. These results suggest that ME2 is a promising
candidate for use in the diagnosis and treatment of GBM.MATERIALS AND METHODS
Clinical Database Analysis
Gene expression and clinical data of 542 patients with glioma
were obtained from The Cancer Genome Atlas (TCGA),
Oncomine (https://www.oncomine.org), and the Chinese
Glioma Genome Atlas (http://www.cgga.org.cn). We applied
the data to create heatmaps, and we added conditional
formatting to Excel cells to show colored heatmaps. We
analyzed the correlation between ME2 and various indicators
and sorted them by category. Then, we sorted the data according
to the clinical molecular classification of glioma and classified by
color to obtain the heatmap with Excel (Microsoft, Redmond,
CA) drawing software.
Cell Culture
Human glioma cell lines SW1783, U251MG, LN229, and U87MG
were obtained fromATCC (Manassas, VA). Cells were cultured atFrontiers in Oncology | www.frontiersin.org 237°C in a 5% CO2 atmosphere and were maintained in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM; HyClone,
Beijing, China) containing 10% fetal bovine serum (Gibco,
Carlsbad, CA). All of the cell lines were authenticated by short-
tandem-repeat profiling.
Quantitative Real-Time Polymerase Chain
Reaction (qRT-PCR)
RNAiso Plus (Invitrogen, Carlsbad, CA) was used to isolate total
RNA from tumor cells. Reverse transcription and RT-PCR were
performed using a RevertAid First Strand cDNA Synthesis Kit
(Vazyme, Nanjing, China) and a SYBR GREEN PCR Kit
(Vazyme, Nanjing, China) according to the manufacturers’
specifications. Actin was used as the endogenous control for
qRT-PCR. The qRT-PCR primer sequences were as follows: b-
actin forward: 5′-CACCATTGGCAATGAGCGGTTC-3′; b-
actin reverse: 5′-AGGTCTTTGCGGATGTCCACGT-3′; ME2
forward: 5′-GCTCAGAACACCTATGGGGA-3′; and ME2
reverse: 5′-CTATTCTGTTATCACAGG-3′. The results were
calculated using the 2-DDCT method (30).
Plasmid Construction
The sh-EGFP, sh-ME2, Flag-Vector, and Flag-ME2 plasmids
were previously constructed in our laboratory. The p3×FLAG-
Myc-CMV™14 expression vector and pLKO.1-puro or pLKO-
Tet-ON-puro vector were purchased from Sigma-Aldrich (San
Francisco, CA).
Cell Transfection
SW1783 and U251MG cells were inoculated in six-well plates at
a density of approximately 60% 12 h before transfection, and 2
mg of Flag-Vector or Flag-ME2 plasmid and 5 mL of
lipofectamine TM 2000 reagent (Invitrogen, Carlsbad, CA),
were added to each well. After 48 h, cells were harvested for
use in subsequent experiments.
The psPAx2 and pMD2.G plasmids were co-transfected with
sh-EGFP or sh-ME2 into HEK293T cells using lipofectamine
TM 2000. The supernatants were collected 48 h and 72 h after
transfection. U87MG and LN229 cells were infected with 1 × 106
recombinant lentivirus transduction units in the presence of
8 mg/mL polybrene (Sigma-Aldrich), and cells were selected by
puromycin (2 µg/mL) until all cells became nonviable in the
blank group.
Western Blot Assay
Total protein of cells was extracted using a 2× sodium dodecyl
sulfate (SDS) loading buffer and was separated by 10% SDS
polyacrylamide gel electrophoresis. Then, protein samples were
transferred onto polyvinylidene fluoride membranes and blocked
with a blocking solution. The membranes were incubated with
primary antibodies overnight at 4°C and with secondary
antibodies for 1 h, and then membranes were washed with 1×
tris-buffered saline with Tween 20 three times. Protein bands
were visualized using chemiluminescence (Meilunbio, Dalian,
China) and analyzed using ImageJ software. The primary
antibodies included ME2 (Abcam, ab139686, 1:1000), MET
(CST, 24294, 1:1000), E-cadherin (CST, 3195, 1:1000),July 2021 | Volume 11 | Article 715593
Yang et al. ME2 Promotes PMT in GBMN-cadherin (CST, 4061, 1:1000), vimentin (CST, 5741, 1:1000),
YKL-40 (BioWorld, BS6564, 1:800), OLIG2 (Santa Cruz, sc-
293163, 1:800), SREBP-1 (Abcam, 28481, 1:1000), ATP–citrate
lyase (ACLY; CST, 13390, 1:1000), ACSS2 (CST, D19C6, 1:1000),
AMPK (CST, 2532, 1:1000), phospho-AMPK (CST, 2531,
1:1000), and b-tubulin (MA5-11732, 1:2000; Thermo Fisher
Scientific) antibodies.
Cell Counting Kit-8 (CCK8) Assay
A total of 2000 transfected cells were placed in 96-well plates and
incubated at 37°C for 72 h. CCK8 solution (Vazyme, Nanjing,
China) was added (10 mL) to each well, and cells were incubated
at 37°C for 2 h. The absorbance of each well at 450 nm
was measured.
Colony Formation Assay
One thousand transfected glioma cells were placed in six-well
plates. Cells were cultured for 15 days in a routine environment,
and the medium was changed every 3 days. The cells were
observed every day until visible cell colonies appeared.
Colonies were fixed with 4% paraformaldehyde for 30 min,
stained with crystal violet for 30 min, and then washed with
phosphate-buffered saline (PBS; HyClone, Beijing, China). The numbers
of colonies were counted under a microscope (MoticAE2000).
Transwell Migration and Invasion Assays
For the migration assay, 8 × 104 transfected cells were
resuspended in serum-free medium and placed in the upper
chamber. For the invasion assay, BD Matrigel basement
membrane (BD Bioscience, Corning, NY) was added to the
upper chamber; the other steps were consistent with the
migration assay. The chambers were incubated for 14 h in
culture medium with 10% fetal bovine serum in the bottom
chambers. Then, the upper chamber was fixed with 4%
paraformaldehyde at 4°C for 30 min and stained with crystal
violet for 30 min. Finally, the cells were imaged under an
inverted microscope.
Wound Healing Assay
Transfected cells were cultured overnight in a 24-well plate at a
density of 1 × 105 cells per well. When the degree of cell fusion
was approximately 90%, a scrape wound was created across the
diameter with a 10-mL pipette tip. The medium was changed to
serum-free DMEM, and the selected location was photographed.
Photographs were taken at the same position 24 h later to
calculate the relative distance of cell movement. The
experiment was repeated three times, and the mean value
was calculated.
Mitochondrial Citric Acid and
Pyruvate Assays
Transfected cells were placed in a 24-well plate at a density of 1 ×
104 cells per well. The medium was replaced with serum-free
medium after 24 h, and cells were incubated at 37°C for 0, 2, 4,
and 6 h. Citric acid and pyruvate levels were measured with a
citric acid and pyruvate assay kit (Jiancheng, Nanjing, China)
according to the manufacturer’s instructions.Frontiers in Oncology | www.frontiersin.org 3Tissue Microarray Immunohistochemistry
Immunohistochemistry was used to detect the protein expression
of ME2 in a human glioma tissue microarray. The tissue
microarray was purchased from Easy Biotrade (Nanjing,
China). The human glioma samples used in this study were
confirmed by a pathologist according to the WHO criteria. The
use of human specimens was approved by the relevant
institutional review boards.
Tissue sections were air-dried, deparaffinized, and rehydrated.
Endogenous peroxidase activity was blocked for 10 min with
H2O2 (3%). Antigen retrieval was performed with citrate buffer
in a pressure cooker for 10 min. A 5% serum-free protein block
from Biosharp (Nanjing, China) was used to block nonspecific
antibody binding for 20 min. Then, slides were incubated
overnight at 4°C with primary antibody and at room
temperature for 30 min with a species-specific secondary
antibody (SA1020; BOSTER, Wuhan, China). Finally, DAB
(AR1022; BOSTER, Wuhan, China) was used to develop the
color for 10 min, after which distilled water was added to stop the
color development. Similar tissue sections immune-stained with
nonspecific IgG were used as negative controls. Protein
expression was quantified using a four-value intensity score (0,
none; 1, weak; 2, moderate; and 3, strong) and a four-value
percentage score (0, <10%; 1,10%–40%; 2,40%–70%; 3, >70%).
Immunofluorescence
Glioma cells were uniformly inoculated in a 24-well plate at a
density of 5 × 104 cells per well. After 16–18 h of culture,
MitoProbe™ JC-1 (Thermo Fisher Scientific, MA,CA) working
solution was added to the wells at a concentration of 300 mL/well,
followed by incubation in the dark at 37°C for 10 min. Then, the
culture solution was removed by suction and the cells were
washed three times with preheated PBS. The cells were added to
500 mL of a preheated PBS solution and immediately observed
under a fluorescence microscope for imaging. ImageJ software
was used to analyze the fluorescence intensity in the fluorescence
images under the same parameter settings, and the relative
fluorescence intensity of the experimental group compared
with the control group was calculated.
Statistical Analysis
All data are presented as the mean ± standard error of the mean
(SEM). Comparisons between groups were analyzed using the
Student’s t test (two groups) or the one-way analysis of variance
(ANOVA; multiple groups) using Prism 8.0 software (GraphPad,
San Diego, CA). P<0.05 represented a statistically significant
difference. All experiments were repeated at least three times.RESULTS
ME2 Is Highly Expressed in GBM and Is
Associated With Overall Survival
Using TCGA data, normal brain tissue samples (n=10) and GBM
tissue samples (n=542) were analyzed. The results confirmed that
ME2 mRNA expression was higher in GBM tissue than inJuly 2021 | Volume 11 | Article 715593
Yang et al. ME2 Promotes PMT in GBMnormal brain tissue (Figure 1A). In addition, ME2 expression
gradually increased from normal brain tissue to low-grade
glioma and then to malignant glioma (Figure 1B). The tissue
microarray results and the score analysis of staining results also
indicated that ME2 expression in normal brain tissue was lower
than that in GBM. (Figures 1C, D). According to CGGA data,
Kaplan–Meier survival analysis showed that patients with GBM
and high ME2 expression had shorter survival times (Figure 1E).
These results suggest that ME2 is highly expressed in GBM and
that its expression is negatively correlated with the total survival
time of patients with GBM.
ME2 Is Positively Correlated With MES
Features in GBM
To investigate the association of ME2 expression with GBM
subtypes, a gene expression heatmap was used to display the
expression of ME2, MES markers, and PN markers. This
investigation revealed that ME2 expression was positively
associated with MES markers (including MET, vimentin, N-
cadherin, and YKL-40) and negatively associated with PN
markers (OLIG2, E-cadherin) (Figure 2A and Table S1). To
confirm these findings, RT-PCR and western blot assays were
used to detect ME2 expression in different glioma cell lines. The
results indicated that ME2 had higher expression in LN229 and
U87MG cells compared with SW1783 and U251MG cells
(Figures 2B, C). The relative protein expression of MES
markers MET and YKL-40 and the PN marker OLIG2 was
detected in four different human glioma cell lines. The
expression levels of MET and YKL-40 in LN229 and U87MG
cells were higher than those in SW1783 and U251MG cells,
whereas OLIG2 had lower expression in LN229 and U87MGFrontiers in Oncology | www.frontiersin.org 4cells; these results suggest that SW1783 and U251MG cells are
associated with the PN phenotype, whereas U87MG and LN229
cells are associated with the MES phenotype (Figure 2D).
Therefore, ME2 is highly expressed in MES-phenotype glioma
cells and is positively correlated with MES features in GBM.
ME2 Promotes the Proliferation of
Glioma Cells
To determine the biological function of ME2, SW1783 and
U251MG cells (PN phenotype) were transfected with a vector
or Flag-ME2 plasmids. The mRNA and protein expressions of
ME2 in the experimental group were significantly increased
compared with those of the control group (Figure 3A, B).
Then, the effects of ME2 on proliferation of glioma cells were
evaluated by CCK8 and colony formation assays. The results
showed that overexpression of ME2 resulted in much greater
proliferation ability compared with the vector group in SW1783
and U251MG cells (Figures 3C–F). Moreover, when ME2 was
knocked down in LN229 and U87MG cells, we found that both
mRNA and protein expression of ME2 were significantly
reduced in the sh-ME2 (knockdown) group compared with the
control group (Figures 4A, B). CCK8 and colony formation
assays were used to confirm proliferation ability; the results
suggested that ME2 knockdown suppressed the proliferation of
LN229 and U87MG cells (Figures 4C–F). Overall, these results
demonstrate that ME2 has a major effect on cell proliferation.
ME2 Promotes the Migration and Invasion
of Glioma Cells
To evaluate the effects of ME2 on cell migration ability, transwell
chamber and wound healing assays were conducted. TheA B
D EC
FIGURE 1 | ME2 expression is upregulated in GBM and associated with overall survival of patients. (A) mRNA levels of ME2 in GBM and normal brain tissues
(*P < 0.05). (B) ME2 expression levels in different grades of glioma and statistics and analysis of positive cells results (**P < 0.01, ***P < 0.0001). (C) Immunohistochemical
staining of ME2 in GBM and normal brain tissues. (D) Protein expression score statistics and analysis of staining immunohistochemical results (*P < 0.05). (E) Association
of ME2 expression with overall survival of patients with GBM (cutoff for ME2 low/high=20.17, P = 0.0423).July 2021 | Volume 11 | Article 715593
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FIGURE 2 | ME2 is positively correlated with mesenchymal features in GBM. (A) Gene expression heat map showing the expression of ME2 and PN and MES
markers in different gliomas. (B) mRNA expression levels of ME2 detected by real-time PCR in SW1783, U251MG, LN229, and U87MG cells (n = 4, **P < 0.01).
(C) Protein expression levels of ME2 in SW1783, U251MG, LN229, and U87MG cells detected by western blotting. (D) Expression of MES markers MET and YKL-
40 and PN marker OLIG2 detected by western blotting in SW1783, U251MG, LN229, and U87MG cells.A B D
E F
C
FIGURE 3 | Overexpression of ME2 promotes proliferation of GBM cells. (A) ME2 overexpression detected by real-time PCR in SW1783 and U251MG cells
(**P < 0.01). (B) Western blotting to confirm ME2 expression in in SW1783 and U251MG cells transfected with vector or Flag-ME2 plasmids. (C, D) Effects of ME2
overexpression on proliferation of SW1783 and U251MG cells determined by CCK-8 assay (*P < 0.05). (E, F) Colony formation assay to determine the colony
formation of glioma cells (***P < 0.0001).Frontiers in Oncology | www.frontiersin.org July 2021 | Volume 11 | Article 7155935
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significantly stronger than that in the control group
(Figures 5A–D), and the number of invading cells was higher
in the Flag-ME2 group compared with the control group,
indicating that ME2 promoted cell invasion in SW1783 and
U251MG cells (Figures 5E, F). Overall, upregulation of ME2
significantly promoted proliferation, migration, and invasion of
the PN-phenotype SW1783 and U251MG cells. We also knocked
down ME2 in LN229 and U87MG cells and found that thisFrontiers in Oncology | www.frontiersin.org 6suppressed migration (Figures 6A, D). Furthermore, we found
that knockdown of ME2 inhibited invasion ability using a
transwell BD Matrigel invasion assay (Figures 6E, F). These
results confirm that ME2 promotes proliferation, migration, and
invasion of GBM cells.
ME2 Promotes PMT of Glioma Cells
It has been suggested that PMT occurs during relapse in patients
with PN-phenotype tumors; this process is extremelyA B D
E F
C
FIGURE 4 | Knockdown of ME2 inhibits cell proliferation in LN229 and U87MG cells. (A) Confirmation of the efficiency of ME2 knockdown in LN229 and U87MG
cells transfected with sh-EGFP or sh-ME2 plasmids by real-time PCR (**P < 0.01, ***P < 0.0001). (B) Western blot to confirm ME2 expression in LN229 and U87MG
cells transfected with sh-EGFP or sh-ME2 plasmids. (C, D) CCK-8 assay to determine the effects of ME2 overexpression on proliferation of LN229 and U87MG cells




FIGURE 5 | Overexpression of ME2 promotes migration and invasion of GBM cells. (A) Representative images of the migration of SW1783 cells transfected with
vector or Flag-ME2 plasmids (***P < 0.0001). (B) Numbers of migrated cells after Flag-ME2 transfection in U251MG cells (***P < 0.0001). (C, D) Wound healing
assays to evaluate the effects of ME2 on migratory ability of SW1783 (C) and U251MG (D) cells (***P < 0.0001). (E, F) Invasion ability of SW1783 (E) and U251MG
(F) cells transfected with vector or Flag-ME2 plasmids determined by transwell invasion assay (***P < 0.0001).July 2021 | Volume 11 | Article 715593
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ME2 promotes PMT of glioma cells, we performed a western blot
assay to detect the expression of MES markers MET, YKL40, N-
cadherin, and vimentin; epithelial marker E-cadherin; and PN
marker OLIG2. The results showed that ME2 overexpression in
SW1783 and U251MG cells upregulated the expression of N-
cadherin, vimentin, YKL40, and MET expression, whereas it
downregulated the expression of E-cadherin and OLIG2,
suggesting that ME2 promotes PMT of glioma cells
(Figure 7A). As expected, ME2 knockdown had the opposite
effects in U87MG and LN229 cells (Figure 7B). Because ME2 is
essential for reactive oxygen species (ROS) homeostasis, we
examined the effects of ME2 on ROS oxidation in glioma cells
using a MitoProbe™ JC-1 fluorescent probe. Green fluorescence
intensity was decreased in the Flag-ME2 group compared with
the control group, suggesting that ME2 inhibited the production
of ROS in mitochondria (Figures 7C, D). Thus, ME2 promotes
PMT of glioma cells and inhibits the production of
mitochondrial ROS.
ME2 Promotes Lipogenesis via the
AMPK–SREBP-1–ACSS2 Pathway
We also investigated the effects of ME2 on the lipogenesis
pathway in glioma cells. Existing studies have confirmed that
acetyl-CoA is the material for lipid synthesis and that acetyl-CoA
develops from the ACLY pathway and the ACSS2 pathway (32).
The heatmap revealed that ACLY was highly expressed in the PN
phenotype, whereas ACSS2 was highly expressed in the MES
phenotype of GBM (Figure 8A and Table S2). The precursor ofFrontiers in Oncology | www.frontiersin.org 7SREBP-1 (pro-SREBP-1) migrates to Golgi and releases the N-
terminal domain with transcriptional activity through a series of
proteolytic processes. The mature SREBP-1 (M-SREBP-1), an
active nuclear form of SREBP, is then translocated into the
nucleus, which activates the transcription of SREBP response
genes, promoting the lipogenic process (33). We used
immunofluorescence to examine the location of SREBP-1 in
cells and found that overexpression of ME2 increased its nuclear
localization (Figures 8B and S1). A western blot assay was then
used to detect the effects of ME2 expression on lipid metabolism–
related proteins in glioma cells. As a result of proteolytic
processes, the molecular weight of pro-SREBP-1 is 120 kDa,
whereas the weight of M-SREBP-1 is only 68 kDa. The western
blot results showed that ME2 overexpression increased the
expression levels of ACSS2 and M-SREBP-1 but decreased
those of phosphorylated AMPK (p-AMPK) (Figure 8C).
Moreover, downregulation of ME2 decreased the expression of
ACSS2 and M-SREBP-1, whereas it increased the expression of
p-AMPK (Figure 8D). No significant changes in ACLY
expression were observed during these experiments.
The mitochondrial malic enzyme ME2 catalyzes malate to
pyruvate and then promotes the citrate cycle that is linked to
fatty acid synthesis (34). We determined the changes in
mitochondrial citric acid and pyruvate concentrations by
chemiluminescence in glioma cells. The concentrations of
mitochondrial pyruvate and citric acid were higher in the Flag-
ME2 group than in the vector group, indicating that ME2
promoted the production of pyruvate and citric acid (Figure 8E).




FIGURE 6 | Knockdown of ME2 inhibits migration and invasion of GBM cells. (A) Representative images of the migration of LN229 cells transfected with vector or
Flag-ME2 plasmids (***P < 0.0001). (B) Numbers of migrated cells after Flag-ME2 transfection in U87MG cells (***P < 0.0001). (C, D) Representative images of the
migration distances of LN229 and U87MG cells transfected with sh-EGFP or sh-ME2 plasmids (***P < 0.0001). (E, F) Invasion ability of LN229 and U87MG cells
transfected with sh-EGFP or sh-ME2 plasmids determined by transwell invasion assay (***P < 0.0001).July 2021 | Volume 11 | Article 715593
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acids mainly via the AMPK–SREBP-1–ACSS2 pathway in
glioma (Figure 8G).DISCUSSION
In this study, we confirmed that ME2 promotes cell proliferation,
migration, and invasion, consistent with previous findings (35).
Importantly, we found that ME2 was correlated with the GBM
MES phenotype and promoted PMT and reprograming of the
lipogenesis pathway via AMPK–SREBP-1–ACSS2 in glioma
cells. These results suggest that ME2 is a candidate for use in
the molecular diagnosis of GBM.
PMT in GBM is an EMT-like process that usually occurs in
patients after radiation therapy and chemotherapy (36–38).
Evidence suggests that PMT is driven by certain restricted
master regulators, including STAT3, C/EBPb, and TAZ (39–
42). Moreover, FoxM1 can promote acquisition of MES features
and PMT in glioma via activation of the EGFR–AKT–GSK3b
signaling pathway (43). Recently, pyruvate kinase 2, a key
enzyme in glucose metabolism, was shown to have significantly
higher expression in the MES subtype of GBM compared with
the PN subtype, suggesting that the metabolic pathway of GBMFrontiers in Oncology | www.frontiersin.org 8may be reprogrammed when PMT occurs (44–46). Previous
studies have indicated that ME2 promotes growth,
transformation, and metastasis of malignant tumors (24–26).
Here, we found that ME2, a metabolic enzyme in the TCA cycle,
is critical for PMT of GBM and is linked to lipogenesis (47).
Uncontrolled regulation of cellular energy and metabolic
reprogramming are important characteristics of malignancy
including EMT and PMT (48–50). Studies have shown that
GBM metabolic phenotypes not only undergo glycolytic
pathway reprogramming but also undergo changes in the
mitochondrial TCA cycle and lipogenesis pathways (22). The de
novo synthesis of fatty acids has emerged as a source of therapeutic
targets for cancers (51). The main substrate for fatty acid synthesis
is cytoplasmic acetyl-CoA, which can be derived from either
ACLY-mediated citrate conversion or ACSS2-mediated acetate
conversion (52, 53). ACLY serves as a cross-link between the TCA
cycle and the de novo synthesis of fatty acids by catalyzing the
formation of acetyl-CoA (54). In this study, we found that ME2
could increase the production of mitochondrial pyruvate and citric
acid but had little effect on the expression of ACLY. This implies
that ACLY has no effect on the de novo synthesis of fatty acids.
Furthermore, ME2, a metabolic enzyme involved in the TCA
cycle, significantly affected the expression of ACSS2, which
converts acetate to acetyl-CoA independently of the TCA cycle.
Previous studies have confirmed that ME2 is essential for ROSA B
DC
FIGURE 7 | ME2 promotes PMT and inhibits the production of ROS in mitochondria. (A, B) Western blots confirming the expression of MET, E-cadherin,
N-cadherin, vimentin, YKL-40, and OLIG2 (A) in SW1783 and U251MG cells transfected with vector or Flag-ME2 plasmids and (B) in LN229 and U87MG cells
transfected with sh-EGFP or sh-ME2 plasmids. (C, D) Changes in ROS in mitochondria of SW1783 and U251MG cells transfected with vector or Flag-ME2 plasmids
detected by fluorescent probe. Green fluorescence represents lipid components oxidized by ROS; red fluorescence represents nonoxidized lipid components.
Fluorescence intensity statistics and analysis by Image J (*P < 0.05).July 2021 | Volume 11 | Article 715593
Yang et al. ME2 Promotes PMT in GBMhomeostasis and energy change (26, 55). Therefore, it is reasonable
to conclude that ME2 may influence ROS production and AMPK
phosphorylation. AMPK is a highly conserved metabolic regulator
that can maintain the intracellular energy balance under
physiological metabolic stress conditions (56). As expected, we
found that ME2 inhibited the production of ROS and AMPK
phosphorylation. Recent studies have indicated that activated
AMPK could inhibit the maturation and nuclear translocation
of SREBP-1 and the subsequent transcriptional activation of
ACSS2 (57, 58). We confirmed that ME2 promotes SREBP-1
maturation and nuclear localization and increases ACSS2
expression, indicating that ME2 upregulates de novo lipogenesis,
probably via AMPK–SREBP-1–ACSS2, in glioma cells.
In conclusion, ME2 promotes PMT of GBM cells, and ACSS2
has an important role in the ME2-induced de novo synthesis ofFrontiers in Oncology | www.frontiersin.org 9fatty acids in glioma cells. These results suggest that ME2 could
provide a new approach for glioma diagnosis and treatment.DATA AVAILABILITY STATEMENT
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FIGURE 8 | ME2 promotes lipogenesis reprogramming in glioma cells. (A) Gene expression heat maps showing expression of ME2, ACLY, and ACSS2 in different
gliomas. (B) Localization of SREBP-1 in U251MG cells observed by immunofluorescence staining. (C, D) Relative changes in citrate and pyruvate concentration (C)
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